Magnesium Taurate, Magnesium Ditaurate, Magnesium Taurinate, 334824-43-0
MAGNESIUM TAURATE – MAGNESIUM TAURATE
CHEMICAL IDENTITY AND DEFINITION
| Parameter |
Information |
| Chemical Name (IUPAC) |
Magnesium bis(2-aminoethanesulfonate) |
| Other Names |
Magnesium Ditaurate, Magnesium Taurinate, Magnesium Taurate, Taurine Magnesium Salt |
| Chemical Formula |
C₄H₁₂MgN₂O₆S₂ |
| Molecular Weight |
~272.6 g/mol |
| CAS Number |
334824-43-0 |
| Chemical Class |
Organic magnesium salt (sulfonate) |
| Appearance |
White to off-white, crystalline powder |
| Odor |
Odorless or faint characteristic odor |
| Physical State (20°C) |
Solid (powder) |
PHYSICAL PROPERTIES
| Property |
Value |
| Appearance |
White to off-white, crystalline powder |
| Odor |
Odorless or faint characteristic odor |
| Molecular Weight |
~272.6 g/mol |
| Elemental Magnesium Content |
~8.9% |
| Solubility in Water (20°C) |
High (freely soluble) |
| Solubility in Ethanol |
Limited or insoluble |
| Taurine Content |
~91.1% (theoretical) |
CHEMICAL PROPERTIES
| Property |
Information |
| Chemical Formula |
C₄H₁₂MgN₂O₆S₂ |
| Molecular Weight |
~272.6 g/mol |
| Chemical Class |
Organic magnesium salt (sulfonate) |
| Structure |
Magnesium salt of taurine (2-aminoethanesulfonic acid) |
| Magnesium Content |
~8.9% (by weight) |
| SMILES |
[Mg+2].[O-]S(=O)(=O)CCN.[O-]S(=O)(=O)CCN |
| Stability |
Stable under normal storage conditions |
| Hygroscopicity |
Moderately hygroscopic |
Chemical Structure:
NH₂-CH₂-CH₂-SO₃⁻
|
NH₂-CH₂-CH₂-SO₃⁻ Mg²⁺
(Magnesium Taurate / Magnesium Ditaurate)
COMPARISON WITH OTHER MAGNESIUM COMPOUNDS
| Compound |
Water Solubility |
Magnesium Content |
Bioavailability |
| Magnesium Taurate |
High |
~8.9% |
Very High |
| Magnesium Citrate |
Low |
~16.2% |
High |
| Magnesium Oxide |
Very Low |
~60% |
Low |
| Magnesium Sulfate |
High |
~20% |
High |
| Magnesium Chloride |
High |
~12% |
High |
| Magnesium Glycinate |
High |
~10% |
Very High |
| Magnesium Lactate |
Moderate |
~12% |
High |
BIOLOGICAL AND PHARMACOLOGICAL PROPERTIES
| Parameter |
Description |
| Essential Mineral |
Magnesium is a cofactor for over 300 enzymatic reactions in the body |
| Taurine Effect |
Taurine is critical for cardiac muscle function and neurotransmission |
| Heart Health |
Supports myocardial contractility, exhibits antiarrhythmic effects |
| Nervous System |
Regulates nerve conduction, has modulatory effects on GABAergic system |
| Cell Protection |
Taurine stabilizes cell membranes and exhibits antioxidant properties |
| Osmotic Balance |
Regulates intracellular osmotic balance |
| Muscle Function |
Essential for muscle contraction and relaxation |
| Metabolic Effect |
May increase insulin sensitivity, supports glucose homeostasis |
PHARMACEUTICAL AND BIOLOGICAL ROLE OF TAURINE
| Property |
Description |
| Chemical Class |
β-aminosulfonic acid (non-protein amino acid) |
| Body Distribution |
High concentrations in skeletal muscle, cardiac muscle, brain and retina |
| Bile Acid Conjugation |
Conjugates with bile acids to aid digestion |
| Antioxidant Activity |
Neutralizes reactive oxygen species (ROS) |
| Cell Membrane Stabilization |
Maintains cell membrane integrity |
| Calcium Homeostasis |
Regulates intracellular calcium levels |
| Neurotransmission |
Modulates GABA and glycine receptors |
MECHANISM OF ACTION
| Step |
Description |
| 1 |
Ingestion of magnesium taurate |
| 2 |
Absorption in the intestine (high bioavailability) |
| 3 |
Taurine and magnesium enter systemic circulation |
| 4 |
Magnesium: Acts as cofactor in 300+ enzymatic reactions |
| 5 |
Taurine: Cell membrane stabilization and antioxidant effects |
| 6 |
Positive inotropic effect on cardiac muscle, antiarrhythmic activity |
| 7 |
Neurotransmitter modulation in the nervous system |
| 8 |
Reduction of oxidative stress, cellular protection |
APPLICATIONS
7.1. Pharmaceutical Applications
| Application |
Description |
| Cardiac Health Support Products |
Magnesium and taurine source in cardioprotective formulations |
| Nervous System Balancing Formulations |
Products supporting neurotransmission |
| Magnesium Supplementation |
High bioavailability form for magnesium deficiency (hypomagnesemia) |
| Stress and Anxiety Management |
Due to balancing effects on the nervous system |
| Cardiovascular Diseases |
Adjunctive therapy in congestive heart failure and hypertension |
7.2. Dietary Supplements
| Application |
Description |
| Tablets and Capsules |
Magnesium and taurine source for daily supplementation |
| Powder Formulations |
For preparation as oral solution |
| Multivitamin/Mineral Complexes |
Magnesium component in mineral blends |
| Sports Supplements |
For muscle function and energy metabolism |
| Sleep Quality |
Due to balancing effects on the nervous system |
7.3. Food Industry
| Application |
Description |
| Food Fortification |
Magnesium and taurine source for fortified foods |
| Functional Beverages |
Use in energy and sports drinks |
| Infant Formula |
Taurine is a mandatory component in some infant formulas |
PHARMACEUTICAL DOSAGE FORMS
| Form |
Description |
| Oral Tablets |
For magnesium supplementation, sustained-release formulations |
| Capsules |
For magnesium supplementation, easy-to-swallow form |
| Powder Formulations |
Flexible dosing option, water-soluble |
| Liquid Formulations |
Drops or oral solutions |
| Effervescent Tablets |
Enhanced solubility and taste |
SAFETY AND TOXICOLOGY
| Parameter |
Value |
| Taurine Safe Supplemental Intake Level |
3 g/day |
| Equivalent Magnesium Taurate Dose |
Approximately 3.3 g/day (300 mg elemental magnesium) |
| Oral LD50 (Rat) |
> 2,000 mg/kg (estimated) |
| Carcinogenicity |
Not classified as carcinogenic |
| Mutagenicity |
Negative in standard tests |
| Reproductive Toxicity |
No evidence of adverse effects |
SIDE EFFECTS AND PRECAUTIONS
| Condition |
Description |
| High Dose Side Effects |
Diarrhea, stomach upset, low blood pressure |
| User Groups Not Recommended |
Those with renal failure, those receiving treatment for cardiac arrhythmias |
| Warning |
Should not be used without consulting a physician |
Drug Interactions:
| Drug Class |
Interaction |
| Antibiotics |
May reduce absorption of some antibiotics (tetracycline, ciprofloxacin) |
| Cardiac Drugs |
Potential interaction with calcium channel blockers and antiarrhythmic drugs |
| Diuretics |
May increase magnesium excretion, supplementation may be required |
| Bisphosphonates |
May reduce their absorption |
REGULATORY STATUS
| Region / Authority |
Status |
| European Union |
Approved as food supplement; as taurine and magnesium source |
| USA (FDA) |
Considered under GRAS (taurine: 21 CFR 184.1924) |
| Turkey |
Approved in Turkish Food Codex as taurine and magnesium source |
| EFSA |
Approved as taurine and magnesium source |
| JECFA (FAO/WHO) |
Taurine and magnesium: ADI not specified |
STORAGE AND SHELF LIFE
| Parameter |
Information |
| Storage Conditions |
Cool (15-25°C), dry, well-ventilated area |
| Container Requirements |
Tightly closed, original packaging, protected from moisture |
| Protect From |
Moisture, strong oxidizing agents |
| Shelf Life |
24-36 months (in unopened original packaging) |
PACKAGING OPTIONS
| Packaging Type |
Quantity |
Material |
| Kraft Bag with PE Inner Liner |
25 kg |
Kraft paper + PE |
| Plastic Bucket |
20-25 kg |
HDPE |
| Aluminum Foil Bag |
1-5 kg |
Laminated aluminum |
| Plastic Bag |
25 kg |
HDPE/LDPE |
TRANSPORT INFORMATION
| Parameter |
Information |
| UN Number |
Not regulated (not a hazardous material) |
| Hazard Class |
Not applicable |
| Packing Group |
Not applicable |
| ADR/RID |
Not regulated |
| IMDG Code |
Not regulated |
| IATA (Air) |
Not regulated |
| Marine Pollutant |
No |
SUMMARY AND CRITICAL WARNINGS
Product Summary
| Parameter |
Value |
| Product |
Magnesium Taurate (Magnesium Ditaurate) |
| CAS Number |
334824-43-0 |
| Appearance |
White to off-white, crystalline powder |
| Molecular Weight |
~272.6 g/mol |
| Magnesium Content |
~8.9% |
| Taurine Content |
~91.1% |
| Primary Function |
Magnesium supplementation, heart and nervous system support |
CRITICAL WARNINGS
High Bioavailability: The taurate form enables active transport of magnesium into cells; offers higher bioavailability compared to other magnesium forms.
Dual Effect: Contains both magnesium and taurine; exhibits synergistic effects on heart health and nervous system.
Taurine Safety: Safe supplemental intake level for taurine is 3 g/day. For magnesium taurate, this corresponds to ~3.3 g/day.
Magnesium Content: Contains 8.9% elemental magnesium; this is lower than other magnesium forms but compensated by high absorption rate.
Special User Groups: Those with renal failure and those receiving treatment for cardiac arrhythmias should not use without consulting a physician.
Drug Interactions: May interact with antibiotics (tetracycline, ciprofloxacin), calcium channel blockers, and bisphosphonates.
Side Effects: High doses may cause diarrhea, stomach upset, and low blood pressure.
Regulatory Status: Approved as taurine and magnesium source by FDA, EFSA, and Turkish Food Codex.
IMPORTANT DISCLAIMER: This Technical Data Sheet (TDS) is for informational purposes only and is prepared based on available technical data. The user is responsible for determining the suitability of the product for their specific application and for complying with all local, national, and international regulations. For complete safety, storage, use, handling, disposal, and regulatory compliance information, refer to the official Safety Data Sheet (SDS/MSDS) provided by the manufacturer/supplier. This document is not a substitute for medical advice.
